

# Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020

<https://marketpublishers.com/r/T9B381D6D1DCEN.html>

Date: July 2020

Pages: 203

Price: US\$ 3,500.00 (Single User License)

ID: T9B381D6D1DCEN

## Abstracts

Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020

### SUMMARY

According to the recently published report 'Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020'; Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 34 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.

The report 'Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020' outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 4, 7, 3, 1, 7 and 1 respectively. Similarly, the

universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Infectious Disease, Gastrointestinal, Hematological Disorders, Ophthalmology, Cardiovascular, Central Nervous System, Metabolic Disorders, Musculoskeletal Disorders and Women's Health which include indications Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Atopic Dermatitis (Atopic Eczema), Coronavirus Disease 2019 (COVID-19), Alopecia Areata, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Asthma, Graft Versus Host Disease (GVHD), Inflammation, Rheumatoid Arthritis, Chronic Myelomonocytic Leukemia (CMML), Essential Thrombocythemia, Glioblastoma Multiforme (GBM), Polycythemia Vera, Primary Myelofibrosis, Psoriasis, Acute Lung Injury, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Anaplastic Astrocytoma, Autoimmune Disorders, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Breast Hyperplasia, Bronchiolitis Obliterans, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Cytokine Release Syndrome (Cytokine Storm), Dermatitis (Eczema), Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Epstein-Barr Virus (HHV-4) Infections, Gastrointestinal Tract Cancer, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Glaucoma, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Juvenile Arthritis, Laryngeal Cancer, Leukemia, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Myeloproliferative Disorders, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Pneumonia, Polymyalgia Rheumatica (PMR), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Proliferative Diabetic Retinopathy (PDR), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thrombocythemia Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Ulcerative Colitis, Vitiligo and Wet (Neovascular/Exudative) Macular Degeneration.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics

Development

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics

Assessment

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies  
Involved in Therapeutics Development

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant  
Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued  
Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product  
Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indications, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Companies, H2 2020 (Contd..1)  
Products under Development by Companies, H2 2020  
Number of Products under Investigation by Universities/Institutes, H2 2020  
Products under Investigation by Universities/Institutes, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by AdastrA Pharmaceuticals Inc, H2 2020  
Pipeline by Aerie Pharmaceuticals Inc, H2 2020  
Pipeline by AstraZeneca Plc, H2 2020  
Pipeline by Bristol-Myers Squibb Co, H2 2020  
Dormant Products, H2 2020  
Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Top 10 Indications, H2 2020  
Number of Products by Mechanism of Actions, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020

### COMPANIES MENTIONED

Adastral Pharmaceuticals Inc  
Aerie Pharmaceuticals Inc  
AstraZeneca Plc  
Bristol-Myers Squibb Co  
Celon Pharma SA  
Concert Pharmaceuticals Inc  
CTI BioPharma Corp  
Eli Lilly and Co  
Hangzhou East China Pharmaceutical Group Co Ltd  
HK inno.N Corp  
Incyte Corp  
Japan Tobacco Inc  
Merck & Co Inc  
Novartis AG  
NS Pharma Inc  
OHM Oncology  
Pfizer Inc  
Sierra Oncology Inc  
Sincere Pharmaceutical Group  
Sino Biopharmaceutical Ltd  
Suzhou Zelgen Biopharmaceutical Co Ltd  
Theravance Biopharma Inc

## I would like to order

Product name: Tyrosine Protein Kinase JAK2 - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/T9B381D6D1DCEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9B381D6D1DCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970